First Turn Management LLC Boosts Stake in Ascendis Pharma A/S (NASDAQ:ASND)

First Turn Management LLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND) by 23.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 186,581 shares of the biotechnology company’s stock after acquiring an additional 34,994 shares during the quarter. Ascendis Pharma A/S makes up 4.1% of First Turn Management LLC’s portfolio, making the stock its 4th biggest holding. First Turn Management LLC owned 0.32% of Ascendis Pharma A/S worth $25,446,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Ocean LLC purchased a new position in Ascendis Pharma A/S during the first quarter worth $36,000. Quadrant Capital Group LLC grew its holdings in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S during the fourth quarter valued at $126,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ASND shares. Oppenheimer upgraded shares of Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research report on Thursday, September 5th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group increased their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. Finally, Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $187.08.

Ascendis Pharma A/S Trading Up 0.8 %

ASND stock opened at $113.81 on Friday. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The firm has a market capitalization of $6.63 billion, a PE ratio of -11.84 and a beta of 0.63. The firm has a 50-day moving average of $132.78 and a two-hundred day moving average of $137.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.